Jim Breitmeyer
Chief Executive Officer Altay Therapeutics Inc.
Jim Breitmeyer, M.D., Ph.D., is Chief Executive Officer and Board Director of Altay Therapeutics, bringing more than 35 years of biotechnology and pharmaceutical leadership experience. He has led clinical development programs that contributed to eight FDA-approved products and has held senior executive roles at Oncternal Therapeutics, Bavarian Nordic, Cadence Pharmaceuticals, Eli Lilly, Applied Molecular Evolution, and Serono. His expertise spans clinical development, regulatory strategy, translational medicine, and business leadership across oncology, rare diseases, immunology, and neuromuscular disorders. Dr. Breitmeyer earned his M.D. and Ph.D. from Washington University School of Medicine and completed fellowships at Harvard Medical School and the Dana-Farber Cancer Institute.
Seminars
- Examining the use of different modalities to address the underlying drivers of muscle degeneration and guide development decisions
- Debating the practical trade-offs between administration, manufacturing and patient accessibility to understand the implications of each modality
- Sharing cross-modality learnings from clinical and translational programsto identify common barriers to pipeline advancement
- Characterizing differences in disease progression trajectories across patient populations to improve endpoint selection
- Designing adaptive and risk-adjusted clinical trial strategies that account for heterogeneous decline patterns and maximize the likelihood of detecting treatment effects
